Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Citations to this article

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Matthew J. Hartwell, … , John E. Levine, James L.M. Ferrara
Matthew J. Hartwell, … , John E. Levine, James L.M. Ferrara
Published February 9, 2017
Citation Information: JCI Insight. 2017;2(3):e89798. https://doi.org/10.1172/jci.insight.89798.
View: Text | PDF | Corrigendum
Clinical Research and Public Health Oncology Transplantation

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival

  • Text
  • PDF
Abstract

BACKGROUND. No laboratory test can predict the risk of nonrelapse mortality (NRM) or severe graft-versus-host disease (GVHD) after hematopoietic cellular transplantation (HCT) prior to the onset of GVHD symptoms. METHODS. Patient blood samples on day 7 after HCT were obtained from a multicenter set of 1,287 patients, and 620 samples were assigned to a training set. We measured the concentrations of 4 GVHD biomarkers (ST2, REG3α, TNFR1, and IL-2Rα) and used them to model 6-month NRM using rigorous cross-validation strategies to identify the best algorithm that defined 2 distinct risk groups. We then applied the final algorithm in an independent test set (n = 309) and validation set (n = 358). RESULTS. A 2-biomarker model using ST2 and REG3α concentrations identified patients with a cumulative incidence of 6-month NRM of 28% in the high-risk group and 7% in the low-risk group (P < 0.001). The algorithm performed equally well in the test set (33% vs. 7%, P < 0.001) and the multicenter validation set (26% vs. 10%, P < 0.001). Sixteen percent, 17%, and 20% of patients were at high risk in the training, test, and validation sets, respectively. GVHD-related mortality was greater in high-risk patients (18% vs. 4%, P < 0.001), as was severe gastrointestinal GVHD (17% vs. 8%, P < 0.001). The same algorithm can be successfully adapted to define 3 distinct risk groups at GVHD onset. CONCLUSION. A biomarker algorithm based on a blood sample taken 7 days after HCT can consistently identify a group of patients at high risk for lethal GVHD and NRM. FUNDING. The National Cancer Institute, American Cancer Society, and the Doris Duke Charitable Foundation.

Authors

Matthew J. Hartwell, Umut Özbek, Ernst Holler, Anne S. Renteria, Hannah Major-Monfried, Pavan Reddy, Mina Aziz, William J. Hogan, Francis Ayuk, Yvonne A. Efebera, Elizabeth O. Hexner, Udomsak Bunworasate, Muna Qayed, Rainer Ordemann, Matthias Wölfl, Stephan Mielke, Attaphol Pawarode, Yi-Bin Chen, Steven Devine, Andrew C. Harris, Madan Jagasia, Carrie L. Kitko, Mark R. Litzow, Nicolaus Kröger, Franco Locatelli, George Morales, Ryotaro Nakamura, Ran Reshef, Wolf Rösler, Daniela Weber, Kitsada Wudhikarn, Gregory A. Yanik, John E. Levine, James L.M. Ferrara

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 Total
Citations: 8 16 17 17 18 20 16 18 11 141
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2022 (17)

Title and authors Publication Year
Graft-versus-host disease: establishing IL-33 as an important costimulatory molecule
James Ferrara
Journal of Clinical Investigation 2022
Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study
E Xue, F Lorentino, M Stanghellini, F Giglio, S Piemontese, D Clerici, F Farina, S Mastaglio, A Bruno, E Campodonico, R Nitti, M Marcatti, A Assanelli, C Corti, F Ciceri, J Peccatori, R Greco
Journal of Clinical Medicine 2022
IL-33 and Soluble ST2 Are Associated With Recurrent Spontaneous Abortion in Early Pregnancy
L Zhao, J Fu, F Ding, J Liu, L Li, Q Song, Y Fu
Frontiers in physiology 2022
Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement
N Lupsa, Á Szegedi, A Gézsi, Z Vuncs, T Masszi, G Mikala, P Reményi, S Deola, A Lakshmanan, A Terranegra, E Buzás, Z Pós
Biomedicines 2022
General Rehabilitation Program after Knee or Hip Replacement Significantly Influences Erythrocytes Oxidative Stress Markers and Serum ST2 Levels
M Idzik, J Poloczek, B Skrzep-Poloczek, E Chełmecka, J Jochem, D Stygar, J Czuczejko
Oxidative Medicine & Cellular Longevity 2022
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation
M Shen, S Hong, R Lou, R Chen, X Zhang, L Xu, Y Wang, C Yan, H Chen, Y Chen, W Han, F Wang, J Wang, K Liu, X Huang, X Mo
Experimental Hematology and Oncology 2022
Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial
Dou L, Peng B, Li X, Wang L, Jia M, Xu L, Li F, Liu D
Trials 2022
Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease
DePriest BP, Li H, Bidgoli A, Onstad L, Couriel D, Lee SJ, Paczesny S
Blood Advances 2022
Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia
Siamakpour-Reihani S, Cao F, Lyu J, Ren Y, Nixon AB, Xie J, Bush AT, Starr MD, Bain JR, Muehlbauer MJ, Ilkayeva O, Byers Kraus V, Huebner JL, Chao NJ, Sung AD
PloS one 2022
Prediction of outcomes after second-line treatment for acute graft-versus-host disease
Vo P, Gooley TA, Carpenter PA, Sorror ML, MacMillan ML, DeFor TE, Martin PJ
Blood Advances 2022
Structure-Activity relationship of 1-(Furan-2ylmethyl)Pyrrolidine-Based Stimulation-2 (ST2) inhibitors for treating graft versus host disease
Yuan X, Jiang H, Fu D, Robida A, Rajanayake K, Yuan H, Wen B, Sun D, Watch BT, Chinnaswamy K, Stuckey JA, Paczesny S, Rech JC, Yang CY
Bioorganic & Medicinal Chemistry 2022
Current Definitions and Clinical Implications of Biomarkers in Graft Versus Host Disease
Bidgoli A, DePriest BP, Saatloo MV, Jiang H, Fu D, Paczesny S
2022
Prospective external validation of biomarkers to predict acute graft-versus-host disease severity.
Robin M, Porcher R, Michonneau D, Taurines L, de Fontbrune FS, Xhaard A, Oriano B, Sutra Del Galy A, Peffault de Latour R, Socié G, Schlageter MH
Blood Advances 2022
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
Etra A, Gergoudis S, Morales G, Spyrou N, Shah J, Kowalyk S, Ayuk F, Baez J, Chanswangphuwana C, Chen YB, Choe H, DeFilipp Z, Gandhi I, Hexner E, Hogan WJ, Holler E, Kapoor U, Kitko CL, Kraus S, Lin JY, Al Malki M, Merli P, Pawarode A, Pulsipher MA, Qayed M, Reshef R, Rösler W, Schechter T, Van Hyfte G, Weber D, Wölfl M, Young R, Özbek U, Ferrara JL, Levine JE
Blood Advances 2022
芦可替尼联合糖皮质激素一线治疗急性移植物抗宿主病对巨细胞病毒激活的影响
2022
Effective treatment of low-risk acute GVHD with itacitinib monotherapy
Etra A, Capellini A, Alousi A, Al Malki MM, Choe H, DeFilipp Z, Hogan WJ, Kitko CL, Ayuk F, Baez J, Gandhi I, Kasikis S, Gleich S, Hexner E, Hoepting M, Kapoor U, Kowalyk S, Kwon D, Langston A, Mielcarek M, Morales G, Özbek U, Qayed M, Reshef R, Rösler W, Spyrou N, Young R, Chen YB, Ferrara JL, Levine JE
Blood 2022
Dynamic forecasting of severe acute graft-versus-host disease after transplantation.
Liu X, Cao Y, Guo Y, Gong X, Feng Y, Wang Y, Wang M, Cui M, Guo W, Zhang L, Zhao N, Song X, Zheng X, Chen X, Shen Q, Zhang S, Song Z, Li L, Feng S, Han M, Zhu X, Jiang E, Chen J
2022

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts